Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(4.77)
# 193
Out of 5,044 analysts
20
Total ratings
75%
Success rate
36.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Assumes: Equal-Weight | $14 → $15 | $19.38 | -22.60% | 1 | Oct 24, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $25 → $29 | $20.29 | +42.93% | 4 | Oct 20, 2025 | |
| MRUS Merus | Downgrades: Equal-Weight | $95 → $97 | $94.81 | +2.31% | 5 | Sep 30, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Overweight | $42 → $45 | $37.38 | +20.39% | 3 | Sep 25, 2025 | |
| RVMD Revolution Medicines | Maintains: Overweight | $67 → $70 | $58.02 | +20.65% | 1 | Sep 11, 2025 | |
| XNCR Xencor | Maintains: Overweight | $33 → $27 | $14.67 | +84.05% | 3 | Aug 7, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $44 | $32.18 | +36.73% | 1 | Jun 26, 2025 | |
| BCAX Bicara Therapeutics | Upgrades: Equal-Weight | $8 | $15.88 | -49.62% | 2 | May 23, 2025 |
Zymeworks
Oct 24, 2025
Assumes: Equal-Weight
Price Target: $14 → $15
Current: $19.38
Upside: -22.60%
Arcus Biosciences
Oct 20, 2025
Maintains: Overweight
Price Target: $25 → $29
Current: $20.29
Upside: +42.93%
Merus
Sep 30, 2025
Downgrades: Equal-Weight
Price Target: $95 → $97
Current: $94.81
Upside: +2.31%
Kiniksa Pharmaceuticals International,
Sep 25, 2025
Maintains: Overweight
Price Target: $42 → $45
Current: $37.38
Upside: +20.39%
Revolution Medicines
Sep 11, 2025
Maintains: Overweight
Price Target: $67 → $70
Current: $58.02
Upside: +20.65%
Xencor
Aug 7, 2025
Maintains: Overweight
Price Target: $33 → $27
Current: $14.67
Upside: +84.05%
IDEAYA Biosciences
Jun 26, 2025
Initiates: Overweight
Price Target: $44
Current: $32.18
Upside: +36.73%
Bicara Therapeutics
May 23, 2025
Upgrades: Equal-Weight
Price Target: $8
Current: $15.88
Upside: -49.62%